Anesthetics:
Indications for BYFAVO:
Induction and maintenance of procedural sedation lasting 30mins or less.
Adult Dosage:
Individualize. Titrate to achieve clinical response. Give by IV inj. Induction: 5mg over 1min; for American Society of Anesthesiologists Physical Status (ASA-PS) III or IV: 2.5–5mg over 1min. Maintenance (as needed): 2.5mg over 15secs; for ASA-PS III or IV: 1.25–2.5mg over 15secs. Must wait ≥2mins prior to administration of any supplemental dose.
Children Dosage:
<18yrs: not established.
Boxed Warning:
Personnel and equipment for monitoring and resuscitation. Risks from concomitant use with opioid analgesics and other sedative-hypnotics.
BYFAVO Warnings/Precautions:
Should be administered only by trained personnel in procedural sedation, detection/management of airway obstruction, hypoventilation, and apnea. Have resuscitative drugs/equipment, supportive ventilation, reversal agent (eg, flumazenil) readily available. Give supplemental oxygen through the recovery period. Continuously monitor for cardiorespiratory effects (esp. in those with obstructive sleep apnea, elderly, ASA-PS III or IV patients). Neonatal sedation: monitor newborns. Pediatric neurotoxicity. Severe hepatic impairment. Elderly. Pregnancy. Labor & delivery. Nursing mothers: monitor infants; consider interrupting breastfeeding, pumping and discarding breast milk during and for 5hrs after administration.
BYFAVO Classification:
Benzodiazepine.
BYFAVO Interactions:
Increased risk of profound sedation, respiratory depression, coma, and death with concomitant CNS depressants, including opioid analgesics, other benzodiazepines, propofol; monitor continuously during and through recovery period; titrate Byfavo when concomitant with opioid analgesics and sedative-hypnotics.
Adverse Reactions:
Hypotension, hypertension, diastolic hyper- or hypotension, systolic hypertension, hypoxia; hypersensitivity reactions.
Generic Drug Availability:
NO
How Supplied:
Single-patient-use vial (12mL)—10
